S&P Futures
4,279.25 -7.25 (-0.17%) Dow Futures
33,938.00 -43.00 (-0.13%) Nasdaq Futures
13,502.75 -20.50 (-0.15%) Russell 2000 Futures
1,995.10 -6.60 (-0.33%) Crude Oil
90.17 -0.33 (-0.36%) Gold
1,765.80 -5.40 (-0.30%)
Agios Pharmaceuticals, Inc. (AGIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.22 |
| Open | 26.22 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 25.27 - 26.22 |
| 52 Week Range | 16.75 - 50.98 |
| Volume | |
| Avg. Volume | 716,993 |
| Market Cap | 1.433B |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGIO
Related Research
- Agios Pharmaceuticals, Inc.The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.RatingFair ValueEconomic Moat8 hours agoArgus Research
- GlobeNewswire
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden – – Following FDA Approval in February, PYRUKYND® Is the First and Only Disease-Modifying Treatment for Adults with PK Deficiency – CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically de
- GlobeNewswire
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
Rahul Ballal, Ph.D. Rahul Ballal, Ph.D., chief executive officer of Imara, joins Agios' board of directors. Cynthia Smith Cynthia Smith, former chief commercial officer of ZS Pharma, joins Agios' board of directors. CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imar
- BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)GlobeNewswire
- Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase DeficiencyGlobeNewswire
- GlobeNewswire
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – CAMBRIDGE, Mass., Aug. 11, 2022
